Ground News

News from pharmafile.com

See all of pharmafile.com news coverage in one place. Discover how pharmafile.com’s media bias informs their coverage and compare with thousands of other news outlets.

Overall, we’ve indexed 169 stories from pharmafile.com over the past 3 months.

Ground News rates pharmafile.com’s media bias as unknown. . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

pharmafile.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about pharmafile.com

Where is pharmafile.com located?pharmafile.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top pharmafile.com News

Stephen Hawking

Dialysis Patient Citizens Applauds Texas Legislature for Passing Historic Bill Expanding Affordable Medigap Access for Dialysis and ALS Patients

70% Center coverage: 10 sources

AUSTIN, Texas, June 23, 2025 /PRNewswire/ -- House Bill 2516 has become public law, a significant victory for Texans living with End-Stage Renal Disease (ESRD), or kidney failure, and Amyotrophic Lateral Sclerosis (ALS). The legislation, championed by Representative Ryan Guillen…See the Story

Haemophilia A: Low Dose Emicizumab Effective, Will Reduce Cost by...

Last Updated on June 24, 2025 by Team THIP New Delhi, June 24 (IANS) Low dose of emicizumab could be as effective as standard dose against Haemophilia A, according to a study led by the Indian Council of Medical Research (ICMR). Emicizumab is a bispecific monoclonal antibody used to treat hemophilia A — a genetic […] The post Haemophilia A: Low dose emicizumab effective, will reduce cost by over 50 pc, says ICMR study appeared first on THIP Medi…See the Story

NHS · Manchester

NHS ConfedExpo 2025: A Platform for Change in UK Health and Care

Introduction This year’s NHS ConfedExpo took place on 11–12 June at Manchester Central, bringing together around 9000 attendees. Among them were over 5,000 health and care leaders, with roughly one in three attendees representing C‑suite roles. The programme featured more than 500 speakers and over 150 exhibitors, establishing it as the UK’s largest health and […]See the Story

EMA Committee Recommends Approval of Sarclisa-VRd Induction in Newly Diagnosed Multiple Myeloma Patients Eligible for Transplant

Open the article to view the coverage from EuropaWire.euEuropean Union See the Story

Roche candidate shows early promise for treating haemophilia A - Pharmafile

Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. Data presented at the 2025 International Society on Thrombosis and Haemostasis Congress on 21 to 25 June, Washington DC, US, indicates that NXT007 may offer haemostatic normalisation in patients (without factor VIII inhibitors). NXT007, developed […] The post Roche candidate shows early promise for treating …Washington State · Washington Read Article

Opterion Health strengthens board with appointments of Rice Powell and Mark Hahn - Pharmafile

Swiss life sciences company Opterion Health has appointed two senior industry figures to its board of directors: Rice Powell, former chairman and CEO of Fresenius Medical Care; and Mark Hahn, chief financial officer (CFO) of Verona Pharma. The appointments mark a strategic milestone as the company prepares for clinical trials of its non-glucose based peritoneal […] The post Opterion Health strengthens board with appointments of Rice Powell and M…Switzerland · Switzerland Read Article

AOTI achieves broad market access in Germany for diabetic foot ulcer therapy - Pharmafile

AOTI, focused on solutions for severe and chronic wounds, has announced that its unique topical wound oxygen (TWO2) therapy has received a positive recommendation from the Federal Joint Committee of Gemeinsamer Bundesausschuss (G-BA) in Germany, the largest potential national market in Europe for its therapy. This marks a major milestone in its goal for international […] The post AOTI achieves broad market access in Germany for diabetic foot ulc…Germany · Germany Read Article

Neurizon’s lead drug crosses blood-brain barrier, reinforcing ALS treatment potential

PK study shows strong brain penetration of NUZ-001 and major active metabolite NUZ-001 Sulfone Both compounds significantly prevented TDP-43 aggregation in a patient-derived ALS neuron model at all tested concentrations Brain concentrations reached matched those needed to reverse TDP-43 aggregation Special Report: Clinical-stage biotech Neurizon Therapeutics has reported encouraging new rodent preclinical pharmacokinetic (PK) data for its lead…Australia · Australia See the Story

Terumo BCT showcases new CAR-T workflow enabling faster cell expansion - Pharmafile

Terumo Blood and Cell Technologies (Terumo BCT) has unveiled a new automated workflow that consolidates three critical CAR-T manufacturing steps — T cell activation, viral transduction and expansion — into a single platform, streamlining production significantly. The protocol, published in Cytotherapy, uses the company’s quantum cell expansion system and demonstrates the potential to deliver over […] The post Terumo BCT showcases new CAR-T workf…Read Article

Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology - Pharmafile

Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland has approved a €5m research and development loan to support the clinical development of nanoapalutamide, Nanoform’s nanocrystalline formulation of apalutamide. This loan will drive the company’s programme towards more sustainable and accessible nanocrystalline solutions. The loan covers up to 50% […] The post Nanoform receives €5m l…Helsinki · Helsinki Read Article

Emerging Technologies for Quality Control of Cell-Based, Advanced Therapy Medicinal Products

Advanced therapy medicinal products (ATMP) are complex medicines based on gene therapy, somatic cell therapy, and tissue engineering. These products a…Riyadh · Riyadh See the Story

News from pharmafile.com

News from pharmafile.com

Information about pharmafile.com

Media Bias Ratings

Factuality

Ownership

Top pharmafile.com News

Dialysis Patient Citizens Applauds Texas Legislature for Passing Historic Bill Expanding Affordable Medigap Access for Dialysis and ALS Patients

Haemophilia A: Low Dose Emicizumab Effective, Will Reduce Cost by...

NHS ConfedExpo 2025: A Platform for Change in UK Health and Care

EMA Committee Recommends Approval of Sarclisa-VRd Induction in Newly Diagnosed Multiple Myeloma Patients Eligible for Transplant

Roche candidate shows early promise for treating haemophilia A - Pharmafile

Opterion Health strengthens board with appointments of Rice Powell and Mark Hahn - Pharmafile

AOTI achieves broad market access in Germany for diabetic foot ulcer therapy - Pharmafile

Neurizon’s lead drug crosses blood-brain barrier, reinforcing ALS treatment potential

Terumo BCT showcases new CAR-T workflow enabling faster cell expansion - Pharmafile

Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology - Pharmafile

Emerging Technologies for Quality Control of Cell-Based, Advanced Therapy Medicinal Products

Similar News Topics

Topics Most Covered by pharmafile.com

Sources Covering Similar Topics

Breaking News Topics Related to pharmafile.com